Panel discussion on AI IN PHARMA SUPPLY CHAIN

Over the past few years, Artificial Intelligence (AI) has been one of the most sought-after technologies of interest by an array of industries, and investment is underway to evaluate its applications. The innovation brought about by new developments in the areas of AI and machine learning is nothing short of spectacular. Solutions based on AI algorithms are finding applications in many areas. A recent study by Yale, surveying 200 chief executives, revealed that nearly half (48%) see healthcare as the primary sector to undergo major changes due to AI advancements (1). Across industries, 73 percent of U.S. companies have already adopted AI in at least some areas of their business, according to a 2023 Emerging Technology Survey (2) conducted by PwC — and generative AI (GenAI) is leading the way. In 2024, AI will start to fundamentally change how business gets done. It will impact how companies grow revenue, conduct everyday operations, engage customers and employees, build new business models, and more. The right AI choices will provide companies a significant edge (3).

The pharmaceutical industry is a recent beneficiary of the trend. The pharmaceutical industry is poised to reap substantial benefit from this technological evolution. In fact, with the increasing pace and complexity of drug discovery, coupled with rising costs and supply chain challenges, adoption of AI will become a critical imperative for successfully navigating the demanding landscape. The rapid adoption of AI is compelling, given its ability to transform vast amounts of information into actionable insights and its synergy with advancements in data-driven technologies. Furthermore, as the volume of data generated in the pharmaceutical industry continues to expand, the capacity of AI to effectively analyze and utilize this information for strategic decision-making becomes increasingly crucial.

AI in pharma is only gaining momentum. There are a growing number of pharmaceutical companies considering – or already using – AI-based solutions in their research, drug discovery, optimizing the drug substance synthesis, formulation and process development, quality control, predictive maintenance, clinical trial data analytics, pharmacovigilance, patient support, dosage control, ongoing post-market research and analysis of treatment results, inventory, and supply chain management, as well as many additional areas (4).

Slowly but steadily, the pharma sector is also becoming the next testing ground for companies looking to use AI to help digitalize and boost their global supply chains. For this special feature, we have invited 20 expert panelists to respond to questions on the use of AI in pharma supply chain, logistics and inventory management. Readers can find their contributed input following my commentary article.

Challenges in the pharmaceutical supply chain
The most significant in the pharmaceutical industry is its historical siloed structure, a consequence of decades-old legacy systems. This data fragmentation obstructs real-time access to essential information for drug manufacturers and distributors. It is essential going forward that organizations strive for a data-centric and user-centric approach allowing visibility of the complete data across all channels – the right information at the right time in the right place (5).

The biggest challenges within pharmaceutical supply chain management include:

• lack of end-to-end visibility
• malfunctions at the manufacturing level
• tight deadlines and costly expedites
• fragmented multimodal networks
• cold chain temperature control and strict handling throughout the entire process
• issues related to drug counterfeiting
• maintaining the highest quality and repeatability of drug manufacturing
• personalized treatment production for individual patients (e.g., T-cell therapies)

How can AI make a difference in the pharma supply chain
AI offers the pharmaceutical industry with the opportunity to solve problems that have been unsolvable with traditional methods of data analysis. Looking at the pharmaceutical supply chain specifically, we’re seeing a growing number of AI-based solutions offering answers to many of the industry’s current challenges.

Companies leverage AI to optimize their pharmaceutical supply chains through predictive analytics, by enhancing demand forecasting, inventory management, and route planning. Real-time data analysis enables better decision-making, reduces delays, and ensures a more responsive and efficient supply chain.

AI analyzes historical data to predict future demand, minimizing excess inventory and reducing costs. Machine learning algorithms optimize routing and logistics for efficient transportation, while real-time monitoring improves visibility into the supply chain. Companies also use AI for risk management, identifying potential disruptions and enabling proactive solutions. The integration of AI technologies fosters agility and responsiveness in adapting to dynamic supply chain challenges.

AI also can mitigate geopolitical risks in supply chains by continuously monitoring global events and analyzing their potential impacts.

Learnings from other industries
The retail and e-commerce sectors, recognized as pioneers in employing AI for supply chain optimization, have much to offer the pharmaceutical industry. These industries use AI for tasks like demand forecasting, inventory management, route optimization, and enhancing customer satisfaction. The pharmaceutical supply chain can benefit from adopting these AI applications.

For example, the sophisticated demand forecasting methods of companies like Amazon could be used to accurately predict pharmaceutical demand, considering variables such as seasonal trends and epidemic outbreaks. In warehouse management, e-commerce’s AI-driven automation technologies, like sorting and packing robots, could be repurposed to improve efficiency and accuracy in pharmaceutical logistics. Similarly, the AI-powered personalized experiences offered by e-commerce platforms could lead to more tailored patient care in the pharma sector. Additionally, the logistics industry’s long-standing use of predictive modelling for transportation can be leveraged to revolutionize the distribution of high-value pharmaceuticals, ensuring reliable delivery to patients dependent on these vital medications.

AI in inventory management and warehouse optimization
AI streamlines inventory management by providing real-time visibility into stock levels, expiration dates, and demand patterns. Warehouse optimization benefits from AI-driven automation, leading to more efficient space utilization and reduced operational costs. AI’s capabilities in data analysis, machine learning, and optimization algorithms make it a powerful tool for improving inventory management and warehouse operations, leading to cost savings, increased efficiency, and enhanced overall supply chain performance.

AI helps analyze historical data, market trends, and various influencing factors to accurately forecast demand.

Here’s how AI improves safety stock management:

• Demand forecasting: AI models can predict future demand more accurately than traditional methods. By considering seasonality, market trends, and other variables, AI helps determine optimal safety stock levels to prevent stockouts during peak demand periods.
• Dynamic adjustments: AI enables real-time adjustments to safety stock levels based on changing market conditions, demand fluctuations, or unexpected events. This dynamic approach ensures that safety stock aligns with the current business environment.
• Supplier and lead time variability: AI models factor in supplier performance and lead time variability, helping companies maintain an appropriate level of safety stock to account for potential delays or disruptions in the supply chain.
• Optimized reorder points: AI algorithms calculate optimal reorder points by considering not only historical data but also external factors like economic indicators, weather patterns, or geopolitical events that might affect supply chain dynamics.
• Reduced excess inventory: By accurately predicting demand and adjusting safety stock levels accordingly, AI helps prevent overstock situations, reducing excess inventory costs and improving overall supply chain efficiency.
• Automation in warehousing: AI-powered robots and automated systems are used in warehouses for picking, packing, and sorting. This automation increases efficiency, reduces human error, and lowers labour costs.

Incorporating AI into safety stock management enhances adaptability and responsiveness, ensuring that companies maintain an optimal balance between meeting customer demand and minimizing holding costs.

Efficient route planning and transportation time

AI significantly contributes to efficient route planning, reducing transportation time and costs in the pharmaceutical supply chain. This not only improves overall efficiency but also enhances the reliability of delivering life-saving drugs to patients. Here’s how:

• Optimized routing: AI algorithms can analyze various factors such as traffic patterns, weather conditions, and road closures in real time to determine the most efficient routes for pharmaceutical transportation. This optimization minimizes delays and transportation costs.
• Dynamic adjustments: AI enables dynamic adjustments to routes based on changing circumstances. For example, if there’s unexpected traffic or a disruption along the planned route, the AI system can quickly recalculate and recommend alternative paths, ensuring timely deliveries.
• Predictive analytics: AI’s predictive analytics can anticipate potential challenges in transportation, allowing companies to proactively address issues before they impact the supply chain. This foresight enhances reliability and efficiency in pharmaceutical logistics.
• Temperature-sensitive shipments: For pharmaceuticals with temperature-sensitive requirements, AI can optimize routes to ensure that products are transported under the appropriate conditions, maintaining the integrity of the medications throughout the journey.
• Reduced costs: Efficient route planning and reduced transportation time contribute to cost savings. AI-driven optimization helps minimize fuel consumption, vehicle wear and tear, and overall logistics expenses, leading to improved cost-efficiency.
• Compliance and security: AI can assist in ensuring compliance with transportation regulations and enhance security measures. This is particularly crucial in the pharmaceutical industry, where maintaining the integrity and safety of products during transit is paramount.
• Integration with other supply chain processes: AI systems can be integrated with other supply chain processes, creating a cohesive and interconnected logistics network. This integration enhances visibility and coordination across different stages of the supply chain.

Finding alternative vendors/suppliers using AI
Many industries use an AI application to find alternative supply sources on short notice. The software generates a list of potential new suppliers by scraping websites for data on suppliers’ finances, customer ratings, sustainability scorecards, diversity scores, intellectual property information such as patents and design awards, customs documents to validate international trading experiences, and real-time alerts from social media and news feeds that can be set by the user to include, for example, financial reports and major hires or terminations. After the software generates a list of potential selected suppliers, the process becomes manual for qualification and approval (6).

Roadmap to support AI adoption in the pharma supply chain
The promise of AI in streamlining the pharma supply chain and delivering the next generation of medicines is clear. However, as is the case with most new technologies, the most updated IT infrastructure and skillset is necessary to take this off the ground. To develop these new capabilities, it is important that an iterative approach be used to scope the project and evaluate the proof of AI development. This approach allows companies to gain confidence in the models and use them as foundations for new service models supported by new abilities and analytical competencies before moving toward mature AI adoption. The high-level steps are as below:

1. Define areas where AI will bring value to business and patients.
2. Ensure the maturity of your data infrastructure.
   –  Artificial Intelligence models need a strong pipeline of clean, normalized data to produce quality results. You will need a digitized ecosystem that gathers historical data on suppliers, manufacturing, orders, transportations, etc. If you don’t have normalized data stored, start collecting it.
3. Begin with a small-scale AI proof of concept.
4. Recruit a skilled team of experts.
5. Foster collaboration.
   – Collaboration is vital for an AI technology project to succeed, especially in the supply chain management sector, not just between global supply chain partners; pharmaceutical companies must also pool resources and ideas to ensure the technology reaches its full potential.
6. Track and optimize key metrics.
   – Continuously enhance performance by adjusting algorithms to meet your desired benchmarks and KPIs. Assess the business impact and plan subsequent AI projects to further improve the drug supply chain.

Challenges in execution / implementation of AI
While AI offers significant potential in revolutionizing the pharmaceutical supply chain, several challenges (7) must be addressed for its effective adoption:

1. Need for high-quality digital data: AI’s utility hinges on high-quality digital information. A lack of digitalized business processes currently impedes immediate AI implementation, necessitating. initial investments in digitalization.
2. Initial infrastructure costs: The expense of establishing new digital infrastructure can be substantial, representing a barrier for some companies. However, these costs often become justifiable as the infrastructure matures.
3. Skillset shortage: A major challenge lies in the scarcity of professionals skilled in data science, data engineering, and digital and analytics, which are crucial for deploying digital technologies.
4. System complexities: AI systems, often cloud-based require significant bandwidth and sometimes specialized hardware, leading to considerable initial investment for supply chain partners.
5. Scalability Factor: The scalability of AI and cloud-based systems may necessitate a larger initial user base or system setup to be effective, requiring in-depth discussion with AI service providers.
6. Cost of training: Adopting AI necessitates personnel training, demanding significant time and financial investment. This can affect business efficiency, during the integration phase.
7. Operational costs: AI-operated machines require maintenance and part replacements, leading to potentially high operational costs due to the complexity and energy requirements of these systems.
8. Regulatory acceptance: The adoption of digital technologies in the pharma industry is still evolving, and regulatory acceptance is progressing slowly. Confidence remains high that stakeholders will recognize the benefits of increased data and algorithm transparency.
9. Limited application in certain scenarios: AI tools may offer less value in stable supplier markets with well-known alternative suppliers and minimal uncertainty. Additionally, AI provides limited advantages in robust partnerships where partners already share comprehensive information (4).

Regardless of the challenges, we believe the pharmaceutical industry’s exploration of AI will lead to faster development of better products to meet more unmet medical needs. AI’s influence will not be limited to specific applications; it will permeate the entire pharmaceutical industry and provide a unified platform for scientists, researchers, and clinicians to share data and insights, encouraging a collaborative culture that will spark groundbreaking discoveries. We foresee AI empowering researchers to explore new scientific avenues more efficiently and cost-effectively, reducing the time it takes to bring life-saving therapies to patients. As AI takes hold, the pharmaceutical industry will evolve and emerge as a more efficient, innovative, and patient-centric entity. AI will be the driving force behind this transformation, ushering in a new era of medical breakthroughs and improved patient outcomes.

Additionally, AI will help increase affordability and access to medicines globally while ensuring that pharmaceutical operations follow high sustainability standards. Finally, AI could help build confidence with regulators and facilitate faster approvals.

In conclusion, AI is poised to revolutionize the pharmaceutical industry by streamlining processes, enhancing research and development, improving supply chain efficiency, and ultimately accelerating drug discovery and delivery of effective medicines to patients faster.

References and notes

1. https://www.cnn.com/2023/06/14/business/artificial-intelligence-ceos-warning/index.html
2. https://www.pwc.com/us/en/tech-effect/emerging-tech/emtech-survey.html
3. https://www.pwc.com/us/en/tech-effect/ai-analytics/ai-predictions.html
4. https://nexocode.com/blog/posts/ai-in-pharma/
5. https://hbr.org/2023/11/how-global-companies-use-ai-to-prevent-supply-chain-disruptions
6. https://nexocode.com/blog/posts/ai-in-drug-supply-chain/
7. https://throughput.world/blog/ai-in-supply-chain-and-logistics/

–

BEENA WOOD
Chief Officer of Safety and Medical Products, ArisGlobal

–

FLAVIEN SUSANNE
VP, head of Chemical Development, Astrazeneca

AI – How digital will revolutionise the Pharma Industry
AI is revolutionizing the pharmaceutical industry across various facets, starting with drug discovery. AI plays a pivotal role in identifying new drug targets by analyzing vast biological data and accelerating the discovery process. Machine learning algorithms sift through genomic, proteomic, and other biological datasets to uncover patterns, relationships, and potential targets for drug development.

AI plays a crucial role in optimizing pharmaceutical process development, streamlining operations, and improving efficiency. Here are some ways AI is employed in this domain:
Process Optimization: AI algorithms analyze vast datasets from previous experiments to identify optimal conditions for pharmaceutical processes. This includes factors like temperature, pressure, and reaction times, leading to more efficient and cost-effective manufacturing processes.

Quality Control: AI enhances quality control by monitoring various parameters in real-time. Smart sensors and AI algorithms can detect deviations from expected values, identifying potential issues early in the manufacturing process and ensuring consistent product quality.

Scale-Up Predictions: Predicting how a process developed in the lab will scale up to large-scale production is a complex task. AI models use data from smaller-scale experiments to predict and optimize conditions for larger-scale manufacturing, reducing the need for extensive trial and error.

Manufacturing benefits from AI-driven automation, ensuring precision and quality control. Smart sensors and AI algorithms monitor production in real-time, detecting anomalies and minimizing errors, ultimately improving overall product quality.

AI’s impact extends to the supply chain by optimizing logistics and forecasting demand. Predictive analytics aids in inventory management, preventing shortages and reducing waste. This results in a more agile and responsive pharmaceutical supply chain.

In summary, AI is reshaping the pharmaceutical landscape by accelerating drug discovery, optimizing processes, improving manufacturing precision, and enhancing supply chain efficiency. The industry is witnessing a transformative wave of innovation driven by artificial intelligence.

–

SAM WHITMARSH
Director of Analytical Science and Digital Transformation, CatSci

1. https://go.crbgroup.com/2023-horizons-life-sciences-report?utm_campaign=Horizons+Life+Sciences+Fall+2023&utm_source=Press+Release
2. https://www.cphi.com/en/digital-products/digital-products/annual-report-2023.html
3. https://www.pharmiweb.jobs/article/cphi-annual-report-predicts-ai-to-transform-all-processes-in-drug-development-by-2026

–

V VENKATANARAYAN
Digital Transformation Leader, Dr. Reddy’s Laboratories

AI offers tremendous potential for the Pharmaceutical Industry
The pharmaceutical industry is exploring various applications of artificial intelligence (AI) to improve efficiency and reduce errors. Some of the areas where AI is being used include:

• Replacing skill-based operations with robotics and Robotic Process Automation (RPA) based review-by-exceptions.
• Handling large sets of data to gain insights on product robustness, yields, and Quality By Design (QBD) by use of ‘Golden Tunnel’.
• Gaining insights of unknown unknowns.
• Using new technologies like digital twins for optimizing research supply chains.
• Managing attrition for skilled manpower and reducing human errors in operations.
• Understanding nuances of equipment and equipment chain asset health to achieve high productivity and therefore cost leadership.
• Completing documentation without human intervention.
• Enabling more industry employees to use digital technologies by leveraging easy-to-use platforms/applications (due to the advent of more and more ‘no-code’ software).

The use of digital technologies and data-based decision-making has already revolutionized the field of drug discovery and development. By leveraging these technologies, researchers can accelerate drug discovery, optimize clinical trials, and enhance personalized medicine. One of the most significant benefits of digital technologies is the ability to analyze large datasets, identify patterns, and predict drug interactions.

There are many benefits to the application of AI in quality control. It is possible to reduce the number of physical tests required by utilizing data analytics and prescriptive suggestions on operations, which offers a tremendous benefit in terms of speed and costs. Using digital technologies for online and at-line testing through PAT, NIR, or Raman-based estimations can also improve turnaround times. By utilizing parametric analysis across all areas of operations, including manufacturing, warehousing, environment monitoring, and testing, it is possible to increase the robustness and efficiency and avoid errors. Another example is using advanced analytics tools such as the ‘Golden Tunnels’ for all operations, which would proactively avoid batch failures by improving Process Performance (PpK) related to CQAs (Critical Quality Attributes). Potential problems and issues could be solved faster by devising ‘Smart Investigators’, which could help apply real-time and quick resolution of any deviations by rapidly assessing all relevant data from the past to help evaluate the deviation in hand, thereby arriving at the right rootcause.

Besides the tremendous potential, the pharmaceutical industry faces several challenges in adopting digital technologies. These challenges include:

1. Prohibitive cost of additional infrastructure in the initial phase: The cost of implementing new digital infrastructure can be high, which can be a barrier to entry for some companies. However, it is important to note that this cost pays for itself once the infrastructure matures.
2. Lack of data science, data engineering and ‘DnA Business Translator’ (Digital and Analytics) skills: The lack of skilled professionals in data science, data engineering, and digital analytics can be a major challenge. These skills are essential for the successful implementation of digital technologies.
3. Acceptance by regulators takes time: The use of digital technologies in the pharma industry is still developing; therefore, acceptance by regulators is evolving slowly. However, I remain very confident that stakeholders will understand the power of increased transparency in data and algorithms.

But regardless of all the challenges, I believe that due to the pharmaceutical industry’s exploration of artificial intelligence (AI), we can expect faster development and better products, which will help meet more unmet medical needs. Additionally, AI will help increase affordability and access to medicines globally while ensuring that pharmaceutical operations follow high sustainability standards. Finally, AI could help build confidence with regulators and facilitate faster approvals.

–

PEDRO CARDOSO VALENTE
R&D Fellow, Modeling & Rapid Prototyping, Hovione FarmaCiência

Embracing AI and Continuous Manufacturing in the Pharmaceutical Industry
The pharmaceutical industry stands on the cusp of a paradigm shift propelled by Artificial Intelligence (AI) and Continuous Manufacturing (CM) which is reshaping the landscape from drug discovery to process development and supply chain optimization.

AI’s Transformative Impact in the Next Five Years
AI is poised to further accelerate pharmaceutical development by streamlining and bridging the gap between Biology, Drug Discovery, CMC development (Chemistry and Manufacturing Controls) and regulatory processes, leading to a decrease in the time-to-market for new drugs. In formulation and process development, AI’s predictive capabilities are enabling faster workflows based on insightful decision-making, which goes hand-in-hand with state-of-the-art technologies such as continuous manufacturing that further enable seamless process development and flexible manufacturing to cope with varying demand.

The pharmaceutical industry’s embrace of AI and CM is not a mere trend but a necessity. The increasing pace and complexity of drug discovery, coupled with rising costs, necessitates a shift towards more efficient technologies. AI’s ability to turn data into actionable knowledge allied with data-driven continuous manufacturing technologies presents a compelling case for its rapid adoption. Furthermore, as data generation in pharmaceuticals grows significantly, AI’s capacity to harness these data for actionable insights becomes indispensable. This speed and flexibility are crucial in responding to global health challenges, as recently demonstrated in the rapid development of COVID-19 vaccines and medicines.

Data-Driven Manufacturing Technologies. Reducing Time to market, and optimizing supply chains and sustainability
The integration of AI with data-driven manufacturing technologies like continuous flow chemistry and continuous manufacturing of solid oral dosage forms is synergistically leading towards reduced time-to-market as well as lean, sustainable, and resilient supply chains. By utilizing digital twins and virtual experimentation, pharmaceutical companies and contract development and manufacturing organizations (CDMOs) are optimizing processes and reducing the need for large-scale testing. This approach not only speeds up development but also enhances the scalability, flexibility and efficiency of manufacturing processes. By optimizing processes and reducing waste and material requirements during development, AI and CM are also contributing to diminishing the industry’s carbon footprint.

Moreover, AI can enable global supply chain optimization, particularly when allied to CM, which provides supply chain flexibility with adjustable production volumes. These technologies enable pharmaceutical companies to respond swiftly to market changes in demand, reducing the reliance on large inventories and enabling more agile operations. In the face of global challenges like the COVID-19 pandemic, this agility is critical for maintaining the supply of essential medicines.

Impact on Quality, Knowledge Management, and Life Cycle Management
Over the past decade, regulatory agencies like the FDA and EMA have increasingly advocated for Continuous Manufacturing (CM) in the pharmaceutical industry, recognizing its potential to enhance quality assurance. This shift, partly driven by the data-intensive nature of CM technologies, has been validated by early adopters who have demonstrated tangible improvements in product quality and manufacturing efficiency. The advent of CM has paved the way for the integration of AI in process monitoring and control, marking a significant leap towards achieving unparalleled efficiency and efficacy in pharmaceutical production by ensuring that potential issues are addressed before they impact the manufacturing process. This innovative approach significantly reduces waste and associated non-quality costs while ensuring adherence to the highest quality standards.

The application of AI extends beyond immediate manufacturing processes and plays a pivotal role in the lifecycle management of pharmaceutical products by analyzing process data over time. AI can identify trends and inefficiencies, guiding process optimizations that not only enhance product quality but also reduce costs.

Furthermore, by strengthening training programs for engineers and operators, AI may help enhance overall knowledge management, ensuring that the workforce is equipped to handle the complexities of modern pharmaceutical production and can help herald a new era of quality, efficiency, and regulatory compliance.

Navigating Challenges and Issues
AI, similarly to CM, is more than a tool to be implemented – it’s a paradigm shift in operational thinking. Developing a coherent and strategic implementation plan requires a deep understanding of the technology and its practical applications in the pharmaceutical industry. The learning curve is often steep, particularly for less science-driven organizations, making it challenging to extract useful components from a noisy general offering and deal with the corresponding change management. As in CM, before the reward, there is often a painful and uncertain path in its adoption.

Furthermore, the quality and impact of AI applications heavily rely on the quality of training and input data, which in turn requires adequate data infrastructure and effective data governance to ensure data integrity, security, and compliance with regulatory standards. This can be particularly challenging to implement considering legacy data and systems. The industry is replete with historical data, often stored in outdated formats and siloed systems, which often poses the dilemma of investment in making legacy data compatible with modern AI systems or opting for a reset, starting fresh with new data collection and management protocols. The former approach risks inefficiencies and compatibility issues, while the latter could lead to a loss of valuable historical data insights, which underlies the moat of established organizations.

Despite these hurdles, the stakes of not embracing AI are significant. Companies that fail to integrate AI into their operations risk falling behind in an increasingly competitive market. Those who navigate this path successfully, however, stand to gain a competitive advantage.

Conclusion
AI is not just a technological advancement – it’s a catalyst for a paradigm shift in the pharmaceutical industry. By embracing AI alongside CM, every phase of drug development, from initial research to clinical trials and regulatory approval is being streamlined, reducing time to market as well as creating more efficient and sustainable supply chains. As we move forward, collaboration and innovation will also be key in harnessing AI’s full potential by enabling effective data sharing and analysis as well as digital twins for improved operational efficiency.

–

ALAN MARCUS
Chief Growth Officer, LabVantage Solutions

NEXT-GEN PHARMA: NAVIGATING THE AI REVOLUTION IN DRUG DEVELOPMENT AND DISTRIBUTION
The pharmaceutical industry stands on the cusp of a revolution, poised to be reshaped by the transformative power of artificial intelligence (AI). In the next five years, AI is expected to permeate every aspect of drug development, from identifying promising targets to designing effective therapies, ensuring patient safety, and optimizing manufacturing. A recent study by Yale, surveying 200 chief executives, revealed that nearly half (48%) see healthcare as the primary sector to undergo major changes due to AI advancements (1).

Imagine a world where AI-powered algorithms swiftly analyze mountains of data, identifying patterns and connections that would elude even the most seasoned scientists. These insights will guide researchers towards novel drug targets, accelerating the discovery process and bringing new hope to patients battling debilitating diseases. Clinical trials, the backbone of drug development, will undergo a metamorphosis under AI’s influence. AI can help streamline patient selection, ensuring that the right individuals participate in the right trials and optimizing the use of valuable resources. By predicting patient outcomes and monitoring safety with unprecedented precision, AI has the potential to pave the way for safer, more effective clinical trials. It will also help advance personalized medicine by analyzing patient data such as genetics, medical history, and lifestyle to predict optimal treatment options.

The manufacturing process, often a bottleneck in drug development, will benefit from AI’s transformative touch. AI-powered systems will become integral in automating tasks, optimizing production schedules, and predicting potential defects. They can be used to monitor production processes continuously, accurately detecting and classifying defects to safeguard the integrity of pharmaceutical products.

Predictive maintenance, once a distant aspiration, will become a reality under AI algorithms that can analyze historical data and operational parameters, foretelling potential equipment failures and process deviations before they disrupt production. This proactive approach will prevent costly downtime, minimize production losses, and maintain the consistent delivery of high-quality pharmaceuticals. Real-time monitoring and control will modernize manufacturing processes into dynamic, self-regulating entities. AI-powered systems will continuously monitor production parameters, quickly identifying any deviations from quality standards. This real-time oversight will enable prompt corrective actions and help maintain consistent product quality throughout the production process. AI’s impact will extend beyond drug development, revolutionizing pharmacovigilance, the critical process of monitoring drug safety after market approval. AI algorithms will tirelessly scan vast amounts of data, identifying adverse drug reactions and potential drug interactions before they jeopardize patient health.

Regulatory compliance, often a complex and burdensome task, will be streamlined by AI’s efficiency. AI will automate the collection, organization, and analysis of data required for regulatory compliance, reducing the time and effort required to meet stringent standards. This automation can assist pharmaceutical companies in remaining compliant with evolving regulations, while also fostering patient trust and safeguarding product safety.

Personalized quality control strategies will emerge as a hallmark of the AI-driven QC/QA paradigm. AI will develop the capability to assess the unique characteristics of each product and manufacturing process, tailoring QC/QA strategies to optimize effectiveness, reduce waste and ensure that every product meets the highest standards of excellence.

On the supply chain side, AI algorithms will have the power to scan extensive data to accurately predict demand, guiding companies in optimizing inventory levels, production schedules, and transportation plans. We can envision the delicate balancing act of inventory management transforming into a symphony of precision under AI’s baton. AI systems will monitor inventory levels in real time, orchestrating replenishment orders with flawless timing, minimizing stockouts and overstocking, and ensuring that the right products are available at the right time. AI’s strategic guidance will elevate route optimization to new heights by deftly navigating the complexities of traffic patterns, weather conditions, and driver availability. This will help chart the most efficient routes to deliver goods swiftly and seamlessly, reducing transportation costs, improving delivery times, and lowering the environmental footprint of supply chains.

We can expect supply chain visibility, once a fragmented puzzle, to become a unified panorama through AI’s ability to bridge silos and integrate data. AI-powered platforms will aggregate information from suppliers, manufacturers, logistics providers, and customers, providing a holistic view of the entire supply chain. Companies can then easily identify bottlenecks, track shipments in real time, and proactively address disruptions, ensuring the smooth flow of goods from start to finish. AI algorithms can also be employed for fraud detection as they can scrutinize transactions, supplier behavior, and customer data to identify anomalies and patterns that signal fraudulent activities, such as invoice fraud, payment scams, and counterfeit products. This proactive defense will safeguard companies’ revenue, protect their reputation, and maintain the integrity of their supply chains.

Furthermore, supply chain collaboration will be amplified by AI’s ability to facilitate communication and streamline information sharing between various stakeholders. AI can bridge the gaps between suppliers, manufacturers, distributors, and retailers, enabling coordinated decision-making and optimizing supply chain performance.

AI’s influence will not be limited to specific applications; it will permeate the entire pharmaceutical industry and provide a unified platform for scientists, researchers, and clinicians to share data and insights, encouraging a collaborative culture that will spark groundbreaking discoveries. We foresee AI empowering researchers to explore new scientific avenues more efficiently and cost-effectively, reducing the time it takes to bring life-saving therapies to patients. As AI takes hold, the pharmaceutical industry will evolve and emerge as a more efficient, innovative, and patient-centric entity. AI will be the driving force behind this transformation, ushering in a new era of medical breakthroughs and improved patient outcomes.

References and notes

1. Yale survey: https://www.cnn.com/2023/06/14/business/artificial-intelligence-ceos-warning/index.html

–

SAJEEV EMMANUEL MEDIKONDA
Head, Corporate Planning & Strategy, Neuland Laboratories Limited

Generative AI: A Game-Changer for the Pharmaceutical Industry, is the Industry ready?

Why is AI development and use in the pharmaceutical industry forecasted to increase rapidly?
The need for shorter development timelines became really apparent during COVID19, and we saw the industry rise to the challenge. This has raised questions regarding the usual development timelines, which along with the significant development we have seen in AI over the last decade has led to the momentum that is being seen & forecasted.
In terms of the development of AI, we have made tremendous strides in the last few years as we now have computing capability more economically available in the last 10 years. We have had the basic machine learning algorithms in place for around half a century now, but it is the availability of computing power and the developments around data management which have truly unleashed the power of AI. The unveiling of Generative AI’s ability to synthesize structured & unstructured information to come up with multimodal solutions has led to further excitement.

How is artificial intelligence (AI) expected to impact the pharmaceutical industry in the next five years?
With the unveiling of Generative AI for the use of public starting with OpenAI and the competition following quickly, we have seen a number of use cases developed which would not have been imaginable even half a decade ago. With these developments now in the rear-view, there are possibilities opening up across the pharmaceutical value chain from discovery to delivery.
Even as we have seen molecules whose discovery was AI driven enter the clinic, we also have examples of ANN (Artificial Neural Network) assisted development of novel co-crystals.

I believe generative AI has the ability to significantly impact Chemical Process Development in a manner similar to how the IT industry is seeing 50%+ efficiencies coming through in coding. With data being appropriately modelled and the advances made in terms of generative AI’s capabilities on text and images, we are not far from AI generating different Routes of Synthesis, check for patent infringements, consider the costs of the different starting materials and suggesting the best possible options. This would reduce both the time required as well as the number of experiments needed for Process Development.
The way AI can accelerate process timelines given the data and the right models, is quite clear. On the other hand, there is also the potential for new discoveries through Generative AI which could allow for more personalized medicines targeting a much wider range of unmet medical needs.

There are applications even when it comes to the manufacturing of drugs as is clear from the development of Industry 4.0 in other sectors. We could see AI being used for advanced process controls, process monitoring, fault detection and trend monitoring. As in other industries, fixed asset monitoring and maintenance could bring in significant value.

There is also significant potential for knowledge management applications which are critical to functions like Quality and Regulatory affairs. As mentioned earlier, there is great potential on the Intellectual Property front too which could lead to significant gains on productivity.

Quality assurance function can see significant benefits as AI models can be developed for various elements of a QA Specialist’s job. For example, in case of an investigation, it would be quick to search for relevant deviations, expedite the investigate process (as potential root causes are AI generated) and create summaries including effective CAPAs (Corrective and Preventive Actions).

What challenges and issues does AI face in the pharmaceutical industry?
The pharmaceutical industry has historically been a laggard in terms of IT adoption, meaning that a lot of players are not ready to take advantage of the AI revolution from a Data readiness perspective. The Data Management practice across the industry would need to be significantly invested in for companies across the value chain to see the benefits of AI in the operations.

Another element is the regulation to which the industry is subject to, which could lead to delays in adoption.

–

ASMARA AGHA
Head of Strategic Sourcing, Nitto Denko Avecia

–

DANIEL KOPPERS
Head of Research and Development, Phlexglobal, PharmaLex Company

Evolving with AI: A Closer Look at Its Role in Pharma Development and Logistics

How is artificial intelligence (AI) expected to impact the pharmaceutical industry in the next five years?
I foresee major advancements in drug discovery and development, with AI algorithms rapidly identifying potential drug candidates, thereby reducing time and costs. I also anticipate a substantial impact on personalized medicine, as AI analyzes patient data to tailor treatments more effectively. In supply chain management, AI will help to predict disruptions and optimize inventory. AI will streamline clinical trials through improved patient recruitment and real-time monitoring. AI will also support regulatory compliance and help industry to quickly adapt to regulatory changes.

Why is AI development and use in the pharmaceutical industry forecasted to increase rapidly?
AI significantly accelerates drug discovery and development by making it possible to efficiently analyze and extract data from the vast amount of data generated in research. Personalized medicine also propels AI adoption, as it enables more precise treatments based on detailed patient data analysis. Increased collaboration between pharmaceutical companies, tech providers, and academic institutions is fostering an environment ripe for AI innovation. These advancements in AI not only promise greater efficiency and effectiveness in drug development but also offer substantial gains in profitability and market competitiveness for pharmaceutical companies.

What challenges and issues does AI face in the pharmaceutical industry?
One of the foremost issues is the quality and availability of data. AI’s value hinges on access to vast, accurate, and consistent datasets, a task complicated by privacy concerns and the proprietary nature of clinical data. The potential for algorithmic bias adds another layer of complexity. The integration of AI into existing infrastructures also presents a significant hurdle, often requiring substantial investment and a shift from legacy systems. Compounding these challenges is a data science skills gap within the industry. The cost of implementing AI solutions, scalability and generalization of AI models, building trust among healthcare professionals and patients, addressing intellectual property issues arising from AI-generated knowledge, and mitigating cybersecurity risks all underscore the need for a collaborative approach.

What are the potential benefits of AI in quality control and quality assurance in the pharmaceutical industry?
Traditional quality check methods can be error prone. AI, with advanced image recognition, can monitor production quality consistently, significantly reducing errors. For example, AI’s ability to analyze patterns from production line sensors can detect manufacturing deviations in real-time, helping to maintain process integrity.
Another benefit is the ability to automate routine tasks in QC and QA, allowing skilled professionals to focus on complex tasks.

With recall management, automated record-keeping ensures comprehensive documentation of manufacturing processes, essential for tracing issues to their source and ensuring consumer safety.
Additionally, AI systems can learn from each data batch, improving their accuracy and efficiency and enabling proactive quality management.

Which industry is ahead in terms of applications of AI in supply chain optimization and are there learnings or applications to the pharma supply chain?
The e-commerce and retail industries are leading the way in applying AI for supply chain optimization, and there’s a lot the pharmaceutical industry can learn from them. For instance, the advanced demand forecasting techniques used by companies like Amazon could be used to accurately predict drug demand, accounting for factors like seasonal trends and epidemic outbreaks. In warehouse management, automation technologies employed in e-commerce – such as AI-driven robots for sorting and packing – could be adapted to enhance efficiency and accuracy. Moreover, the way e-commerce platforms offer personalized customer experiences using AI can inspire similar approaches in the pharma sector, potentially leading to more personalized patient care. Another key takeaway is the use of AI for supply chain transparency and traceability in retail, which could ensure drug authenticity and regulatory compliance. Dynamic pricing models and predictive maintenance strategies used in retail and e-commerce could be tailored to pharma’s direct-to-consumer models and manufacturing plant operations. Finally, the sophisticated route optimization models used in e-commerce logistics could improve the efficiency of pharmaceutical deliveries.

What, in your opinion, would be the application of AI in demand forecasting?
By harnessing advanced data analysis, AI algorithms delve into historical sales data, market trends, and consumer behaviors, offering real-time insights and allowing for agile responses to market fluctuations. AI’s predictive analytics are particularly valuable for forecasting demand for new products, even in the absence of historical data, by analyzing similar products and market trends. Furthermore, AI-driven forecasts can be customized for specific markets, ensuring relevance and accuracy.

Will AI be useful in inventory management and warehouse optimization?
I can see AI driving significant improvements in how inventory is tracked, managed, and optimized. AI algorithms are adept at analyzing complex data patterns, enabling more accurate demand forecasting and ensuring that inventory levels are closely aligned with market demand. In warehouse optimization, AI can streamline operations through automated sorting, picking, and packing processes, enhancing efficiency and reducing human error. Additionally, AI-driven predictive maintenance can foresee equipment failures before they occur, minimizing downtime.

Will AI enable Pharma companies to achieve efficient route planning, reduce transportation time, and improve overall supply chain efficiency?
By integrating AI into logistics and distribution strategies, I anticipate significant improvements in route optimization, leading to reduced transportation times and enhanced supply chain efficiency. AI algorithms can analyze vast amounts of data, including traffic patterns, weather conditions, and delivery schedules, to identify the most efficient routes and modes of transportation. Furthermore, AI’s predictive capabilities can foresee potential disruptions, allowing for proactive adjustments to our logistics plans. This level of optimization is crucial in the pharmaceutical industry, where timely delivery can be critical.

The contents of this article are solely the opinion of the author and do not represent the opinions of PharmaLex GmbH or its parent Cencora. PharmaLex and Cencora strongly encourage readers to review all available information related to the topics mentioned herein and to rely on their own experience and expertise in making decisions related thereto.

–

BARBARA OWCZAREK
Senior Quality Assurance Specialist, Polpharma

Development of medicinal products and ensuring their quality in the era of AI
The pharmaceutical industry is developing very dynamically. New challenges, such as the COVID-19 pandemic or armed conflicts, are constantly emerging, significantly affecting the provision of pharmacotherapy and medicines to patients. The use of artificial intelligence in the pharmaceutical industry to improve processes related to logistics, resource management, production and control and quality assurance is growing rapidly. The use of AI at the early stage of the development of medicinal products is also significant here. This topic is so current and dynamic that it also generates many doubts and questions regarding, for example, the security of the data used. FDA 2023 published a discussion paper (1), which discusses and considers aspects of AI in the pharmaceutical sector.

The use of AI in the development of medicinal products
The process of searching and developing the synthesis of new biologically active molecules is very tedious and time-consuming. Moreover, modelling the molecule’s interaction with the receptor to find its proper configuration is another aspect that needs to be carefully considered and checked. This includes a field for AI cooperation to support researchers at a much faster pace in searching and designing synthesis paths for new molecules or modifications of existing molecules. The use of AI in modelling pharmacokinetic or pharmacodynamic (2) reactions is significant and may contribute to making the effects of therapy much more effective and safer for the patient (3).

The process of developing formulations and technologies for producing biosimilar drugs or drugs containing small biologically active molecules will also be significantly accelerated thanks to AI. Determining the design space based on the QbD approach will be much simpler, and simulations of potential interactions and the product ageing process in specific conditions will significantly save money without performing many technological tests using raw materials. This does not mean, however, that such trials will not be created because manufacturers still have substrates from many suppliers that may have different physicochemical properties even within the same substance. However, the use of AI, awareness of potential interactions between substances, and the forecast of its stability significantly increase the chance of minimising technological trials and obtaining a ready prototype faster (4).

The use of AI in ensuring and controlling the quality of medicinal products
Artificial intelligence puts predictive analytics at the forefront of quality assurance. Using historical data and machine learning algorithms, you can more quickly identify potential defects and deviations arising during production and significantly impacting quality. This proactive approach allows the implementation of preventive measures that will identify potential quality problems before they occur. Real-time monitoring and continuous improvement become possible with AI-powered insights (5).

Also, the requirements related to the processing of changes in the production of medicinal products are carried out in dedicated, appropriately validated systems. AI would significantly improve the efficiency of processing changes in these systems, especially since these are repeatable procedures. Also, using sensors and manufacturing process monitoring systems based on artificial intelligence can play a key role in quality control. These systems can collect real-time data, monitor quality parameters and identify deviations. Using adaptive algorithms, artificial intelligence can identify patterns, trends and deviations that may be difficult for humans to detect, ensuring quick resolution of quality problems and predicting quality parameters for subsequent batches (6).

Challenges related to the use of AI
Despite the lucrative visions of using AI in many areas related to the development and production of medicinal products, some questions arise about how to ensure the reliability of data obtained thanks to AI and how to protect this data. The reliability of the results and data obtained thanks to AI should also be considered. Of course, using AI in the pharmaceutical industry is a step towards ensuring data consistency, controlling and accelerating the drug development process, and optimising their production.. Still, people working with AI should bear in mind limited confidence in the results obtained. Appropriate training in this area should also cover employees at all levels – from the operator to supervisors and directors, to provide space for discussion. What is obvious is that the final recipient of medicines is the patient. Therefore, the data received from AI should be verified so that the patient receives the highest quality product without compromising his or her health.

References and notes

1. www.fda.gov/media/165743/download (available date: 07.12.2023)
2. Chavda V.P., Ertas Y.N., Walhekar V., Modh D., Doshi A., Shah N., Anand K., Chhabria M. Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds. Front. Pharmacol. 2021;12:702611. doi: 10.3389/fphar.2021.702611.
3. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics. 2023 Jul 10;15(7):1916. doi:10.3390/pharmaceutics15071916
4. Lodhi DS, Verma M, Golani P, Pawar AS, Nagdev S. Impact Artificial Intelligence in the Pharmaceutical Industry on Working Culture: A Review. Scopus Indexed [Internet]. 2022 Feb. 28 [cited 2023 Dec. 10];15(1):5771-80. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/2539
5. Hansa Choudhary, Anta Sharma, Dharmendra Ahuja, Int. J. Pharm. Sci. Rev. Res., 81(1), July – August 2023; Article No. 27, Pages: 159-164, http://dx.doi.org/10.47583/ijpsrr.2023.v81i01.027
6. Kavasidis I., Lallas E., Gerogiannis V.C., Charitou T., Karageorgos A. Predictive Maintenance in Pharmaceutical Manufacturing Lines Using Deep Transformers. Procedia Comput. Sci. 2023;220:576–583. doi: 10.1016/j.procs.2023.03.073.

–

NIMA YAZDANPANAH
Principal, Procegence

Digitalization and AI from Molecule to the Market
I would divide the question into different applications, tools, and then corresponding benefits and challenges, considering the diversity of activities and implications in the pharmaceutical industry from discovery to manufacturing and supply chain.

The broader term to cover all applicable tools and applications would be “Digitalization”, which includes a diversity of platforms and approaches, from humble databases to sophisticated high-fidelity simulations. On the stages and applications, the roles of AI and Digitalization have been applied to

• Faster Discovery: e.g. Molecular interaction modeling and in-silico design of new drugs
• Better Process Development: e.g. Retrosynthesis tools for route optimization, Computational Fluid Dynamic (CFD) for equipment characterization
• Process Control and Manufacturing: e.g. Predictive maintenance, Model Predictive Control (MPC), reduced error, Digital Twins
• Supply Chain and Logistics: e.g. Scheduling, inventory management, external vendors/CMOs monitoring and managing, better quality control, and fewer recalls
• Management and enterprise level: e.g. Visualization of process/product data and alignment with business metrics, running scenarios for demand/supply forecasting
• Regulatory: e.g. Advanced analytics, orthogonal methods, Real Time Release testing.

The benefits of the Digitalization approach have been demonstrated in different industries (e.g. semiconductor) and in the biopharmaceutical industry, which I’m not going to repeat here; rather, I will provide one prominent example of the benefits from one of our projects at the end of this interview. Instead, I’d focus on the workflow (and challenges) associated with the development and application of these tools.

The fundamental requirement for the Digitalization and AI is data and knowledge, following the data-information-knowledge-value nexus. The AI algorithms should be trained on data (clean and contextualized, including metadata) from that particular product, process, or company. Therefore, the first step toward AI and Digitalization starts with developing a digital database of material, equipment, process, analytical, and batch records. These databases should be customized based on the products and processes of the company, with fields of data (curated) that will be used for the next step.

The decision on the extent of the database and subsequently AI and Digitalization tools development will come from the context of use. Are we interested in optimizing a single Unit Operation? Then we can narrow the database and model to input/out material, equipment, and PAT/process data. Do we have higher goals and would like to modernize our manufacturing practice and scheduling and supply chain? Then we need to expand the database to cover many more types of data, frequencies, and contexts, as well as develop a diversity of models and AI tools.

The second aspect of the Digitalization and AI is knowledge and digesting data based on physics, chemistry, applications, and other variations. The AI (a black box) and simulation tools are actually very “stupid” and rather should be designed, trained, checked, and validated by human intelligence. For example, (a real industry case study) a blind computational model would tell you a reactor would have the highest kLa at 1200 rpm, which makes sense by propagation of mathematical equations. However, the scientist knows that the maximum rpm for the industrial reactor is around 150 rpm, so the AI model was useless.

The third aspect is the robustness of the tools, if the models will be deployed on the field, for example, for process control, and will be used by technical engineers. If the “AI-enabled” control system requires constant monitoring and intervention by a data scientist, then field deployment and the reliability of the process will be jeopardized. In addition, the computation cost and logistic complications of deploying these models for manufacturing platforms should be considered during the design and implementation.

Model governance and Life Cycle Management of the AI and models is another important aspect. Keeping models valid and updated with new data/changes, documentation, routine testing and maintenance, knowledge management of the model’s integrity, and personnel rollover and knowledge transfer, are some of the critical aspects of the model governance.

I tried to shed light on some aspects of the AI and Digitalization in the pharmaceutical industry. Utilizing AI and computational models and simulation is an organizational effort, that requires a decent budget, a dedicated team, management support, and a multidisciplinary endeavor. The true benefits cannot be achieved by just purchasing a software.

We help our clients with different applications and scales of Digitalization and AI, from physic-informed AI and Digital Twin, to process design and control, to regulatory. As Procegence is a service/solution provider, our clients come with a diversity of readiness, expectations, budget, and timelines. We surveyed our delivered projects over the past three years and calculated the client’s savings and benefits where they used modeling and simulation (AI and Digital Twin) on a variety of modalities, processes, geography, and scale. Their savings have been a 60% reduction in development cost, 30% reduction of operation cost (optimized process is a continuous profit), 40% shorter development time, 30% improvement of quality, 20% better sustainability metrics, and 20% improvement on business KPIs.

Here I give you one short example with significant time and cost savings and tremendous profit for a commercialization case: A midsize US-based innovator drug company was trying to bring a complex product to the market via a combination of in-house development and CDMO and CMO support. They had a few kilograms of the API from phase 3, short timeline, and a limited budget. Through utilizing modeling and simulation and AI and Digital Twins, we helped them bring the product to the market 9 months faster than the originally planned timeline, with a lower cost, and actually faster regulatory approval. The patients got access to the product 9 months sooner, and the company made hundreds of millions of dollars by lunching the product 9 months sooner.

For more information on this subject refer to:
Yazdanpanah, N., (2020) Process Simulation and Mathematical Modelling for Process Scale-up and Technology Transfer: Development and Manufacturing of Active Pharmaceutical Ingredients, Chemistry Today, 38(6), 39-43.
Yazdanpanah, N., (2023), Interview: The Value of Modeling and Simulation in Biopharma Process Development, AspenTech, https://sitecoreadmin.aspentech.com/en/resources/blog/the-value-of-modeling-and-simulation-in-biopharma-process-development

–

DAMIANA GENTILI1, CHIARA RIGOTTI2
1. Quality Unit Director & QP, Procos
2. Supply Chain & Sourcing Manager, Procos

Artificial Intelligence (AI) within the pharmaceutical sector: an evolving tableau for the next future!
The swift evolution of artificial intelligence (AI) stands poised to exert a profound influence on the pharmaceutical industry over the upcoming half-decade. This transformation finds its core momentum in the burgeoning utilization of AI technologies specifically tailored for drug discovery. Noteworthy investments are channeling into AI-driven initiatives aimed at revolutionizing the drug development landscape.

The evolving tableau of Artificial Intelligence (AI) within the pharmaceutical sector, particularly its sway over manufacturing and supply chain optimization, presents an intriguing narrative. Industry executives are projecting AI to wield substantial force in reshaping pharmaceutical landscapes within the next five years. The sphere of drug discovery is anticipated to witness routine deliveries of FDA-approved drugs, potentially within a trimmed 2–5-year timeline. This perceptual shift signifies a significant turn towards embracing AI as a credible contender within the industry. AI’s reach extends well beyond the confines of drug discovery, demonstrating its potential to streamline various operational facets. Its pronounced impact on quality control and assurance within pharmaceuticals is proof of this potential. AI algorithms and machine learning models are lending precision and speed to inspections, especially in discerning defects that may elude human scrutiny. Concurrently, in quality assurance, AI integration into critical systems, such as deviation programs, ensures alignment with historical data, ensuring consistent application of quality management systems and preempting recurring issues, thus fortifying productivity and product quality.

The technology’s ability to analyze extensive datasets, such as images and sensor data, allows for precise defect identification, enhancing inspection accuracy while expediting the process. Companies are leveraging AI in critical quality systems, like Deviation programs, to ensure consistency in Quality Management Systems (QMS) and prevent failed Corrective and Preventive Actions (CAPAs), thereby maintaining high-quality standards.

Moreover, the indispensable role of AI in ensuring regulatory compliance within the pharmaceutical domain cannot be overstated. Their unmatched data processing capabilities are instrumental in aiding businesses to navigate intricate regulatory terrains with enhanced precision and efficiency. In real-time, AI systems analyze copious amounts of data, enabling the early detection of anomalies that might threaten potential compliance risks, such as indicators of money laundering or insider trading activities. Increasing this ability is AI’s predictive capabilities, empowering organizations to anticipate future risks based on historical patterns, thereby fostering a proactive compliance approach.
Nevertheless, the integration of AI into manufacturing operations needs a deep understanding of its applications subject to regulatory oversight, such as cGMP (current Good Manufacturing Practice) compliance. Applicants must grapple with data integrity, privacy, and cybersecurity challenges as manufacturing equipment becomes interconnected into networks, maintaining stewardship of generated data while ensuring product quality and manufacturing standards.

AI’s reach extends further into supply chain optimization, poised to revolutionize this area as well. Companies spanning diverse industries, including pharmaceuticals, are placing heightened emphasis on sustainability in selecting supply chain partners, catalyzing the adoption of novel production methods geared towards reducing waste and costs. AI’s integration into supply chain processes is poised to optimize routes, curtail inventory, elevate service levels, and increase overall efficiency by facilitating streamlined route planning, curtailing transportation time, and enhancing warehouse management.

The promising forecast of the API market signals a pivotal shift in pharmaceutical and biotech landscapes. Specialized entities collaborating to craft and manufacture API for clinical trials and commercial products are emblematic of this evolving paradigm. This evolutionary trend, underscored by escalated outsourcing to concentrate on core competencies like R&D and marketing, indicates considerable prospects for market expansion.

In sum, AI’s involving impact spanning drug discovery, quality control, regulatory compliance, and supply chain optimization is reshaping the framework of the pharmaceutical industry. As technological advancements continue relentlessly, the evolving role of AI is lined up to grow further, serving as the forerunner of innovation, efficiency, and transformation within the sector.
The track of AI’s progression within pharmaceuticals emphasizes its increasingly pivotal role. Its precision in demand forecasting, supply chain optimization, and transformative metamorphosis in drug development firmly establish AI as the cornerstone of innovation and efficiency within the pharmaceutical domain. The horizon is ripe with opportunities for AI integration, indicating heightened precision, efficiency, and transformative strides in both drug discovery and manufacturing.

Sources

• CPHI Annual Industry Report and Survey 2023
• How AI Can Help Regulatory Compliance – Datarails
• (2) The Future of API Process Development: The Role of Artificial Intelligence | LinkedIn
• Artificial Intelligence Revolutionizes Merchant API Manufacturing as Market Expands at 6.97% CAGR (yahoo.com)
• Artificial Intelligence Discussion Paper (fda.gov)

–

RORY MACDONALD
Senior Chemical Engineer, Quotient Sciences

AI accelerated pharmaceutical supply chains – who can keep up?

How is artificial intelligence (AI) expected to impact the pharmaceutical industry in the next five years?
Over the next five years, innovative deployment of AI is likely to be disruptive to the pharmaceutical industry, with successful early adopters reaping the rewards. Due to the regulatory and safety considerations associated with AI, initial utilisation in the pharmaceutical industry is likely to be in areas less subject to regulatory control. Improved scheduling and materials use within supply chains through deployment of AI is likely one of the first areas where we will see an impact as there is both a low regulatory burden and high amount of cross-over with other industries. AI is already in use for the design and selection of the new medicines – this is likely to grow exponentially, particularly with new complex biological products. The collation together of clinical data into a written report for a regulator is often the rate limiting step in bringing a new medicine to market and maximising patent coverage – AI has the potential to accelerate this, however it requires every step and piece of information to be digitised. In addition to pharmaceutical companies accelerating drug development, AI could be used by regulators to improve the quality, speed and robustness of their review of new medicines for release to market. For innovators in process development, AI assisted digital twins are likely to lead to much more rapid and efficient scale up along with shortened drug development timelines. Within five years we may also see companies gaining significant advantages through fully digitised manufacturing and testing with AI assisted real time release. A fully digitised and AI assisted pharmaceutical industry will deliver a wide range of benefits, however I think the greatest impact will be increased levels of innovation through enabling more humans to work proactively and creatively.

Why is AI development and use in the pharmaceutical industry forecasted to increase rapidly?
AI development and use in the pharmaceutical industry is forecasted to increase rapidly due to the high value of pharmaceuticals and the potential gains that early adopters could make. Innovative providers of AI products and services are likely to target the pharmaceutical industry over others due to the scope for return on investment being higher – this is likely to help with rapid deployment compared to other industries.

What challenges and issues does AI face in the pharmaceutical industry?
AI can only provide a useful output if it is provided with high quality digital information – a lack of wider digitalisation of business processes is an issue that is preventing immediate use of new AI technologies. Prior to being able to fully leverage AI, companies will first need to invest in digitalisation of their processes. Regulatory burdens are also a challenge, but equally an essential guiding hand, in the deployment of AI within the pharmaceutical industry. Due to perceived regulatory limitations, it is likely that AI will be kept away from quality critical decisions to begin with and will instead be deployed to save time and increase the efficiency of work performed by humans. Over time I think that regulatory limitations in using AI will be alleviated through a shift in mindset whereby 100% reliability is not expected and similar approaches to the management of work performed by humans will be used.

What are the potential benefits of AI in quality control and quality assurance in the pharmaceutical industry?
Within Quality Control and Assurance I think that digitalisation of all GMP data entries and validated hard coded software to check this will deliver the most significant benefits. Humans, with our unrivalled capacity for creative thinking, waste our time performing repetitive checking tasks that an automated and validated piece of software could do better. Although AI could be deployed within Quality Control and Assurance, it is likely to remain a tool to aid human decisions as the validation of a non-stable system may not be possible. Although AI is likely to be a tool rather than a replacement for human Quality decisions, it is expected to have enormous benefits through the ability to analyse more data at once and identify anomalies. Large Language Models (LLMs) could also be used to interrogate large numbers of quality documents to audit them against a Quality Management System (QMS), identify patterns or provide deep insights when queried. Most crucially, AI assistance will free up more time for humans to apply critical and creative thinking to ensuring Quality Control and Assurance.

How are companies actually taking advantage of AI technology to optimize their supply chains?
Within the automotive and food industries there are companies out there actively using AI to optimise supply chains. For food and drink, AI technologies and preceding forms of digital twin, are used to blend together input batches or make adjustments to processes to ensure product attributes remain the same between output batches. Some innovative pharmaceutical companies are also using digital twin to reduce product variability and improve use of materials. Within the automotive industry AI is beginning to help reduce inventory levels further through improved scheduling and stock management – early adopters of AI in the pharmaceutical industry are also taking advantage of this.

Which industry is ahead in terms of applications of AI in supply chain optimization and are there learnings, applications to pharma supply chain?
The automotive industry, like pharmaceuticals, have long complex supply chains that they are beginning to use AI to optimise. The automotive industry have also had success in deploying AI for improved quality control of manufactured components – there are learnings here for the pharmaceutical industry that are already spilling over. The pharmaceutical industry is also able to leverage advances made in this area as technology providers work across industries. Semi-conductor manufacturers have also made significant advances with regards to deploying digital twins and this is crossing over into pharmaceuticals through leading digital twin software providers working in both sectors.

Will AI improve performance and reduce inventory while increasing service levels, optimizing routes?
There is no doubt that AI will improve performance, reduce inventory, increase service levels, optimise routes and improve manufacturing processes – however this can only happen if the relevant business operations are digitised.

What in your opinion would be the application of AI in demand forecasting?
An AI model with a training dataset of previous medical demand data along with influencing factors and a forecast of those influencing factors could have the potential to make better and more detailed forecasts than experienced humans, leading to better inventory management, reduced stock outs and reduced waste. For demand forecasting to be fully effective the information needs to be shared across the supply chain and between companies.

Will AI be useful in inventory management and warehouse optimization?
AI assisted inventory management and warehouse optimisation is a low hanging fruit for the pharmaceutical industry due to the advances already made by leading online retailers.

Will AI enable Pharma companies to achieve efficient route planning, reduce transportation time, and improve overall supply chain efficiency in the supply chain?
In most cases in the pharmaceutical industry, the supply chain is spread across numerous companies rather than it being under the control of one organisation. In some cases, for the largest pharmaceutical companies, there will be scope for end-to-end supply chain optimisation by AI as there will be digitised operation and communication throughout. To improve the efficiency of the overall supply chain in the wider pharmaceutical industry we will need to find a way for digitised and automated communication between organisations along with a fair method of agreeing optimal distribution between competing organisations.

–

MICHAEL DE LA TORRE
CEO, Redica Systems

The Role of AI in Pharmaceutical Quality and Regulatory
In nearly every industry, AI/ML will have an enormous impact over the next few years. It’s difficult to name an area in any given business that won’t be impacted.

In the pharmaceutical industry, plenty has already been written about AI/ML’s role in recent drug discovery innovation, and it has led to some remarkable successes. For example, the deep learning-assisted discovery of an antibiotic targeting Acinetobacter baumannii was a scientific triumph that generated a storm of publicity (1).

Much less attention has been given to the impact of AI/ML in the post-discovery pharmaceutical lifecycle, which is the lion’s share of decisions made in the life of a drug. Yet there are equally important opportunities related to how drugs are brought to market, how quality and compliance are improved, and how risks to both companies and consumers are reduced.

AI/ML’s Impact on Post-Approval Stages
Focusing on post-approval stages, AI/ML will have a big impact on:

• Improving patient safety
• Improving regulatory compliance
• Reducing or predicting drug shortages
• De-risking the supply chain

All four of these are highly interrelated, but let’s focus on de-risking the supply chain.

How to De-Risk Your Pharma Supply Chain with AI
It’s important to realize that all AI problems start as data problems. With the 21st-century explosion of data creation, we’ve seen a corresponding exponential growth in “dirty data” and data noise. The vast majority of dirty data is essentially unstructured, disorganized data.

While AI can consume a wide variety of data for inference, in most cases, for AI to be trained, it needs structured, labeled, and sufficiently large datasets. This means that there is no magic bullet in your AI journey. These are highly complex problems with layers of interconnections, and human decision-making in complex systems requires purpose-built AI. General-purpose AI isn’t very good at helping humans in highly specialized fields.

Executed properly, AI can become a pharma company’s recommendation engine on highly complex data problems that span the internal and external environment and that are highly secure.

Here’s a basic outline of the steps required to execute properly.

Data Preparation phase (Get clean and complete data relevant to the problem you are trying to solve) – data engineering and supervised models for linking and labeling data, connected data models with structured, labeled, and linked data … if you don’t do this, you are simply cherry-picking from the clean data that you have or potentially hunting down spurious relationships.

a. Identify components of your products – if they are not all in one system, have different naming conventions, etc.
b. Build supply chain map down to the component level (N Tier)
c. Understand cross-correlations across your own product portfolio
d. Structure and link internal data

Analytics phase
a. Scoring
b. Hunt for clusters/ pattern recognition, correlations
c. Analyze candidates for impact (causal effects)

Integration phase
a. Plugging models into production workflows so humans can use the data

Recommendation phase
a. Once a purpose-built AI has been fed a structured dataset, it can begin to provide real value to human experts – imagine an AI suggesting a first draft FDA response to a 483, for example.

Once a pharmaceutical company has built this capability, it can begin to leverage AI to:

• Identify compliance and/or patient safety risks
• Monitor key parties in the supply chain
• Efficiently prepare the company to react effectively to identified risks

All of this is possible while saving human experts from the more menial data wrangling and monitoring tasks, freeing them up for more valuable uses of their time.

Linking Patient Safety to Supply Chain Management
Many risks to patient safety and, by extension, to the sponsor’s business are rooted in poor quality and/or poor compliance with cGMP being allowed to persist in the supply chain. Despite a sponsor’s best efforts in writing an iron-clad partnership agreement with suppliers like CMOs and excipient or API manufacturers, a sponsor must have reliable systems to verify that those suppliers aren’t getting alarming enforcement actions from regulators. AI/ML can help build better alerting mechanisms.

For example, if an FDA Investigator issues a 483 to a CMO, any sponsor using that CMO should be made aware in a timely manner, and likewise, if that 483 is followed up by a Warning Letter.

If something important happens anywhere in your supply chain, or even in the supply chain of others, that might negatively impact your product’s ultimate quality, AI can help your team answer the following questions:

How widespread is this issue?
a. “Looking at enforcement documents, recalls, adverse events…the issue first appeared 2 years ago, and multiple companies have been affected, including 2 of your suppliers and 1 of your competitors”

Do we have this problem?
a. “Looking at batch records, lab tests, deviations and investigations, complaints, and audit records…there is a high likelihood that you have this issue. Here is the highlighted evidence and the confidence intervals for each item…”

What’s next?
a. Notify your team and collaborate on a remediation
b. Get alerts on the ongoing development of this topic
c. Acknowledge and archive

Here’s a summary of how we see the role of AI in Quality and Regulatory:

Regulatory Considerations
Sponsors that intelligently leverage AI/ML in their post-approval business processes, especially those related to Quality Assurance/Control and Regulatory Surveillance, will be able to meaningfully reduce their compliance risks. As AI/ML helps them improve their Quality Management Maturity (QMM), they will be able to evolve from reactive inspection readiness to proactive. One of our favorite industry aphorisms is, “You don’t get inspection-ready; you have to be inspection-ready.”

As far as regulatory guidance on this topic, there is little so far for post-approval uses of AI/ML, despite an FDA discussion paper that offers glimpses into its thinking (2).

Fortunately, the U.S. regulatory experts we speak to say this is a problem already covered by existing FDA guidance, even if AI/ML is not explicitly mentioned. FDA’s position seems to be that the various Current Good Practices standards, like cGMP, cGVP, cGCP, etc., will still apply in a world permeated by AI/ML.

In Five Years…
No matter how AI/ML gets integrated into the pharmaceutical industry, its great potential for both patient benefit and enhanced corporate profitability ensures that within the next five years, we will start seeing such tools in wide use throughout the business.

We also expect the industry and regulatory authorities to develop a clearer understanding of where and how AI/ML tools can best serve within validated processes.

And that future — not so far away — is faster, smoother, and safer.

References and notes

1. Cesaro, A., de la Fuente-Nunez, C. Antibiotic identified by AI. Nat Chem Biol 19, 1296–1298 (2023). https://doi.org/10.1038/s41589-023-01448-6
2. Artificial Intelligence in Drug Manufacturing. https://www.fda.gov/media/165743/download
3. The Latest in Drug Shortages – https://www.fda.gov/drugs/news-events-human-drugs/latest-drug-shortages#:~:text=The%20specific%20authorities%20to%20enhance,which%20certain%20drugs%20are%20manufactured.

–

EDUARD CAYÓN
Chief Scientific Officer, Rephine

Artificial intelligence to power every aspect of the pharmaceutical industry

How is artificial intelligence (AI) expected to impact the pharmaceutical industry in the next five years?
Artificial Intelligence (AI) is expected to significantly impact the pharmaceutical industry in various ways over the next five years:

AI can help pharmaceutical companies navigate the complex regulatory landscape by keeping track of changing regulations and ensuring compliance.

AI enhances drug discovery and development by quickly identifying potential candidates and predicting compound effectiveness, speeding up the process and reducing costs.

AI aids in creating personalized medicine by analysing large datasets, including genetics, to tailor drugs to individual genetic profiles, enhancing treatment effectiveness.

AI can streamline the clinical trial process by identifying suitable candidates more efficiently. It can also monitor trials in real-time to ensure safety and efficacy, and even predict outcomes based on early data.

AI can optimize pharmaceutical manufacturing processes for efficiency, cost-effectiveness, and compliance with regulatory standards. It can also improve supply chain logistics, predicting demand and ensuring the timely delivery of medicines. AI is being used to develop more accurate diagnostic tools, which can detect diseases earlier and more accurately. This early detection can lead to more effective treatments.

AI applications improve patient engagement by offering customized medication reminders, health tracking, and personalized advice, leading to better health outcomes.

Why is AI development and use in the pharmaceutical industry forecasted to increase rapidly?

The forecast for rapid increase in AI development and use in the pharmaceutical industry is driven by several key factors.

Regulatory bodies like the FDA & EMA are increasingly recognizing the potential of AI in the pharmaceutical industry and are beginning to provide guidelines and support for its integration, which encourages more companies to adopt AI technologies.

The increasing availability of extensive biomedical data, including genetic, molecular, and clinical information, enables AI to develop more sophisticated and accurate models, as AI excels with large datasets.

The traditional drug development process is time-consuming and costly. AI can significantly reduce the time and expense involved in bringing a new drug to market, a particularly appealing aspect in the wake of urgent global health challenges like the COVID-19 pandemic.

The move towards personalized medicine is accelerating, and AI is a key tool in developing treatments tailored to individual genetic profiles, lifestyle factors, and other personal health data.

There is a significant increase in investment from both the public and private sectors in AI for healthcare and pharmaceuticals. This financial support is driving more research, development, and implementation of AI technologies.

What challenges and issues does AI face in the pharmaceutical industry?
Pharmaceutical industry faces several challenges and issues:

AI applications must comply with regulations, which can be complex and vary across different countries and regions. Ensuring that AI systems meet these standards can be a significant challenge.

Improving interpretability and trust in AI in the pharmaceutical industry involves making AI decision-making processes more transparent, especially for complex models like deep learning. This is crucial for building trust among healthcare professionals and the public. It’s closely linked to the need for rigorous validation and testing of AI models to ensure their accuracy and safety in drug development and patient care.

Improving data quality and availability in the pharmaceutical industry is essential for effective AI application. The challenge lies in accessing high-quality, diverse, and comprehensive datasets, as pharmaceutical data is often scattered, incomplete, or inconsistent. Additionally, patient privacy and regulatory constraints restrict data access. Compounding this issue is the industry’s hesitation to share data due to intellectual property concerns.

Another challenge is Integration with legacy systems, adapting to existing workflows, and ensuring that staff are trained to use new AI tools effectively.

Developing and implementing AI solutions can be expensive and resource-intensive. This includes costs related to data collection, model development, computational resources, and ongoing maintenance.

Adapting to AI in a timely manner is essential for maintaining a competitive edge. At the same time, AI in pharmaceuticals raises ethical issues such as bias in drug development and clinical trials, where AI might inadvertently favour certain populations over others.

What are the potential benefits of AI in quality control and quality assurance in the pharmaceutical industry?
AI has the potential to significantly enhance quality control and quality assurance in the pharmaceutical industry.

AI algorithms can analyse large datasets more quickly and accurately than human operators. This can lead to more efficient detection of anomalies or quality issues in pharmaceutical products, reducing the risk of errors. AI can process and interpret complex data from various sources, such as raw material quality, manufacturing parameters, and environmental conditions, leading to a more comprehensive understanding of factors affecting product quality.

AI can predict equipment failures before they occur by analysing patterns from sensor data. This predictive maintenance helps in avoiding unexpected downtimes and ensures consistent quality in manufacturing processes.

AI-powered visual inspection systems can identify defects and inconsistencies in products more reliably than the human eye, ensuring higher product quality and safety.

AI can optimize manufacturing processes by analysing data and suggesting adjustments to improve efficiency, reduce waste, and maintain consistent product quality. AI enables real-time monitoring of production processes, allowing for immediate adjustments to maintain quality standards.

AI can assist in ensuring compliance with regulatory standards by automating the process of data collection and reporting, reducing the risk of non-compliance due to human error.

In quality assurance, AI can facilitate the development of personalized medicine by ensuring that drugs are produced with the precise composition and dosage suited to individual patient needs.

How are companies actually taking advantage of AI technology to optimize their supply chains?
Companies are leveraging AI technology in various innovative ways to optimize their supply chains, enhancing efficiency, reducing costs, and improving overall performance:

AI algorithms analyse historical sales data, market trends, consumer behaviour, and external factors like weather or economic indicators to predict future product demand accurately. This helps in optimizing inventory levels and reducing waste. AI also helps in optimizing shipping routes and logistics.

AI-powered robots and automated systems are used in warehouses for picking, packing, and sorting. This automation increases efficiency, reduces human error, and lowers labour costs.

AI enhances supplier selection and management by analysing performance and risk data, and automates procurement processes.

AI uses audit data from manufacturers and distributors for predictive insights and risk management, streamlining supply chain optimization. AI systems can analyse extensive data collected from audits. This analysis includes evaluating performance metrics, compliance levels, and operational practices.

By integrating AI in analysing audit data, companies can gain deeper insights into the behaviours and potential failures within their supply chain, leading to more informed decision-making and a robust, efficient supply chain management strategy.

Which industry is ahead in terms of applications of AI in supply chain optimization and are there learnings, applications to pharma supply chain?
The electronics and retail industries, known for their technological innovation and large-scale implementation, respectively, offer valuable insights for AI applications in supply chain optimization.

What in your opinion would be the application of AI in demand forecasting?
AI’s application in demand forecasting brings about a paradigm shift from reactive to proactive management, helping businesses anticipate market changes, optimize inventory, and align production with consumer demand more effectively.

–

ARVIND SINGH
Executive Director, Global Supply Chain, SK Pharmteco

KISHORE HOTHA
Global Vice President – AR&D, Veranova

Navigating the Data-Driven Transformation in Pharmaceutical Supply Chains
 
Streamlining Pharmaceutical Supply Chains with AI
Integrating Artificial Intelligence (AI) into pharmaceutical supply chains is heralding a new dawn of operational efficiency and agility. Advanced AI algorithms are pivotal to accurately forecast demand, optimize stock levels, and minimize waste. This shift will transform inventory management from reactive to proactive and real-time monitoring systems will help enable quick response times during disruptions and ensure robust supply chain continuity.

AI as a Catalyst for Change 
AI is a tool and a catalyst for change in pharmaceutical supply chains. Beyond predictive analytics, AI facilitates smarter, data-driven drug development and manufacturing decisions. From molecular drug design to patient outcome predictions, AI is likely to redefine traditional approaches to pharmaceutical logistics. By analyzing vast datasets, AI algorithms can identify patterns and insights which in turn, can inform strategic planning and operational efficiency to drive the industry towards more agile and responsive supply chains.

Navigating the Challenges of AI Integration
The road to AI integration in pharmaceutical supply chains is full of hurdles. Data privacy is a key concern: since AI systems are able to ‘learn’ from and make predictions about their users, it is crucial that steps are taken by regulatory bodies to protect sensitive information. Additionally, many intricacies are involved with merging AI with established systems. The successful implementation of AI across different systems therefore requires extensive expertise and collaboration.
The talent gap in AI expertise is also becoming increasingly pronounced and ethical concerns surrounding the decision-making processes of AI systems continue to provoke discussion. As such, these challenges necessitate a strategic and thoughtful approach to AI integration, balancing innovation with regulatory compliance and data stewardship.

The Future Outlook for AI in Pharma 
The future trajectory for AI in the pharmaceutical sector is marked by an increasing trend toward widespread adoption and sophistication. Within the next five years, AI will become an essential fixture in supply chain operations, characterized by more intelligent algorithms and heightened automation. The move toward decentralized supply chains powered by AI is likely to reduce risks. In addition, advanced risk assessment tools will provide deeper insights into potential supply chain disruptions. Integrating AI with blockchain promises a new level of transparency and traceability, allowing for the rise of self-adaptive supply chains which can respond dynamically to the shifting landscape of healthcare needs.

Enhancing Data Accessibility for AI Advancement
A wealth of data resides in the later pharmaceutical development and manufacturing stages. Yet, it often remains unutilized, locked within the confines of individual companies. The reluctance to share proprietary information may gradually diminish as companies recognize the importance of leveraging AI and machine learning (ML) to remain competitive in supply chain optimization. Collaborative efforts and data pooling could become more commonplace, unlocking the full potential of AI/ML and providing shared benefits that outweigh the risks of data sharing in the long run.

The Challenge of Data Sharing in Pharma 
The data-sharing problem is particularly acute within Contract Development and Manufacturing Organizations (CDMOs), where customer-protected IP reigns supreme. The prevalent business model of strict confidentiality hampers the aggregation of the diverse datasets necessary for AI/ML to operate effectively. New business models that support secure data sharing while protecting client interests could catalyze a leap forward in pharmaceutical supply chain management.

Prospects of Collective Data Utilization 
The prospects for AI in pharmaceuticals hinge on the industry’s willingness to foster a culture of data sharing. Collaborative databases could improve AI/ML applications immensely, offering enriched insights and more robust development pipelines. Stakeholders must balance the traditional ethos of competition and secrecy against the benefits of shared intelligence, which could usher in a new era of innovation and efficiency in pharmaceutical supply chains.

Embracing the AI Evolution: A Collaborative Blueprint for the Pharma Industry 
AI’s role in reshaping pharmaceutical supply chains is evident. The evolution of AI in this context promises enhanced efficiency and better alignment with global healthcare needs, representing a vital step towards a future where healthcare delivery is efficient and patient-centered. The industry’s move towards a more integrated strategy, inspired by the successful AI applications in global supply chains, sets a precedent for pharmaceutical companies. This blueprint addresses current challenges and leverages AI’s full potential, signifying a paradigm shift towards innovation and shared success. Despite the hurdles of technology integration, data management, and ethical governance, the applications of AI in global supply chains, as demonstrated by leading companies, provide a roadmap for the pharmaceutical industry to embrace and evolve towards a more collaborative, data-centric approach.